Maria Themeli, Amsterdam AMC, T cell sensitivity and persistence, blood cancers, z-Movi, Cell Avidity analysisPress releases

New study published in Translational Medicine highlights cell avidity’s power as a functional biomarker for improved CAR-T design in preventing tumor escape

Using cell avidity measurements and traditional immuno-assays, the researchers successfully demonstrated that co-expression of costimulatory receptors along with an FDA approved BCMA and CD19 CAR can improve both durability of potential treatments as well as persistence for common blood cancers.
Kassandra Barbetsea
23 January 2022

Join our newsletter

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By agreeing to receive marketing communications, you subscribe to our newsletter. You can change your mind at any time by clicking the unsubscribe link in any marketing email you receive from us. By submitting the form you agree to LUMICKS' privacy policy.

Download our webinar recording:

 

Download our Cell Therapy (CAR-T, TCR, NK) applications deck